Laurence A. Fissette
Waver, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: November 05, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 06, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 25, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Journal: The New England journal of medicine
Published: February 15, 2023
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Journal: The Journal of infectious diseases
Published: May 27, 2022
Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants.
Journal: Human vaccines & immunotherapeutics
Published: January 18, 2020
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 31, 2018
Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
Journal: Vaccine
Published: September 12, 2018
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.
Journal: The journals of gerontology. Series A, Biological sciences and medical sciences
Published: March 02, 2018
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
Journal: The Journal of infectious diseases
Published: October 30, 2017
Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.
Journal: Frontiers in immunology
Published: April 19, 2017
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Journal: The Journal of infectious diseases
Published: May 19, 2016
Last Updated: 09/26/2026